日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study

HIV-1成熟抑制剂GSK3640254联合两种核苷类逆转录酶抑制剂治疗未接受过抗逆转录病毒治疗的成年患者的疗效和安全性（DOMINO）：一项随机2b期研究的24周结果

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103567
Joshi, Samit R; Cordova, Ezequiel; Mitha, Essack; Castagna, Antonella; Ramgopal, Moti; Llibre, Josep M; Potthoff, Anja; Chernova, Oksana E; Nuñez, Sebastian A; Man, Choy; Jeffrey, Jerry L; Fishman, Cindy; Oyee, James; Joshi, Aditya; Zhang, Ying; Bainbridge, Veronica; Wynne, Brian; Lataillade, Max
HIV
GSK3
微生物学
发表日期：2025
文献求助 收藏

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study

在未接受过抗逆转录病毒治疗的成人患者中，HIV-1成熟抑制剂GSK3640254联合多替拉韦作为双药方案的疗效和安全性（DYNAMIC）：一项随机2b期研究的24周结果

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103566
Joshi, Samit R; Masiá, Mar; Mitha, Essack; Castagna, Antonella; Cordova, Ezequiel; Ramgopal, Moti; Gaudion, Alison; Karthika, Supriya; Oyee, James; Bainbridge, Veronica; Wynne, Brian; Lataillade, Max
HIV
GSK3
微生物学
发表日期：2025
文献求助 收藏

Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study

患者改用固定剂量复方多替拉韦/拉米夫定双药方案后的疗效：SALSA 研究的 48 周结果

期刊:Aids and Behavior
影响因子:2.4
doi:10.1007/s10461-024-04479-9
Kumar, Princy; Clarke, Amanda E; Jonsson-Oldenbüttel, Celia; Deltoro, Miguel García; Di Giambenedetto, Simona; Brites, Carlos; Hocqueloux, Laurent; Lu, Po-Liang; Oyee, James; Oglesby, Alan; Wynne, Brian; Jones, Bryn; Evitt, Lee A; Fox, Dainielle; Kisare, Michelle; Priest, Julie
ALS
发表日期：2025
文献求助 收藏

Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study

极低水平病毒血症、炎症生物标志物及相关基线变量：TANGO随机研究的三年结果

期刊:Open Forum Infectious Diseases
影响因子:3.8
doi:10.1093/ofid/ofad626
Wang, Ruolan; Underwood, Mark; Llibre, Josep M; Bernal Morell, Enrique; Brinson, Cynthia; Sanz Moreno, José; Scholten, Stefan; Moore, Richard; Saggu, Parminder; Oyee, James; Moodley, Riya; Wynne, Brian; Kisare, Michelle; Jones, Bryn; Ait-Khaled, Mounir
微生物学
炎症/感染
炎症
发表日期：2024
文献求助 收藏

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

在成人人类免疫缺陷病毒1型（HIV-1）感染者中，改用多替拉韦/拉米夫定双药方案与继续使用三药或四药方案维持病毒抑制的疗效和安全性：3期非劣效性SALSA随机试验第48周结果

期刊:Clinical Infectious Diseases
影响因子:7.3
doi:10.1093/cid/ciac130
Llibre, Josep M; Brites, Carlos; Cheng, Chien-Yu; Osiyemi, Olayemi; Galera, Carlos; Hocqueloux, Laurent; Maggiolo, Franco; Degen, Olaf; Taylor, Stephen; Blair, Elizabeth; Man, Choy; Wynne, Brian; Oyee, James; Underwood, Mark; Curtis, Lloyd; Bontempo, Gilda; van Wyk, Jean
ALS
HIV
炎症/感染
微生物学
Human
免疫/内分泌
发表日期：2023
文献求助 收藏

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure

在将HLA-B*5701筛查作为风险缓解措施的十年间，阿巴卡韦超敏反应报告率

期刊:Pharmacotherapy
影响因子:3.4
doi:10.1002/phar.2196
Stainsby, Chris M; Perger, Teodora M; Vannappagari, Vani; Mounzer, Karam C; Hsu, Ricky K; Henegar, Cassidy E; Oyee, James; Urbaityte, Rimgaile; Lane, Charlotte E; Carter, Lindsay M; Pakes, Gary E; Shaefer, Mark S
发表日期：2019
文献求助 收藏

Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation

更正：一线化疗治疗局部晚期或转移性非小细胞肺癌成人患者的临床疗效和成本效益：系统评价和经济评估

期刊:Health Technology Assessment
影响因子:4
doi:10.3310/hta17310-c201505
Brown, T; Pilkington, G; Bagust, A; Boland, A; Oyee, J; Tudur Smith, C; Blundell, M; Lai, M; Martin Saborido, C; Greenhalgh, J; Dundar, Y; Dickson, R
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal

利妥昔单抗用于滤泡性非霍奇金淋巴瘤一线维持治疗：NICE单项技术评估

期刊:Pharmacoeconomics
影响因子:4.6
doi:10.1007/s40273-013-0043-8
Greenhalgh, Janette; Bagust, Adrian; Boland, Angela; Blundell, Michaela; Oyee, James; Beale, Sophie; Dundar, Yenal; Hockenhull, Juliet; Proudlove, Chris; Chu, Patrick
淋巴瘤
发表日期：2013
文献求助 收藏

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

一线放化疗治疗局部晚期非小细胞肺癌成人患者的临床疗效：系统评价

期刊:Health Technology Assessment
影响因子:4
doi:10.3310/hta17060
Brown, T; Pilkington, G; Boland, A; Oyee, J; Tudur Smith, C; Dundar, Y; Richards, E; Yang, R; Dickson, R
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review

CYP2D6基因分型在接受他莫昔芬治疗的乳腺癌女性患者管理中的临床有效性和成本效益：一项系统评价

期刊:Health Technology Assessment
影响因子:4
doi:10.3310/hta15330
Fleeman, N; Martin Saborido, C; Payne, K; Boland, A; Dickson, R; Dundar, Y; Fernández Santander, A; Howell, S; Newman, W; Oyee, J; Walley, T
肿瘤免疫
肿瘤
乳腺癌
发表日期：2011
文献求助 收藏